Regeneron Pharmaceuticals Stock News

The company announced their current antibody treatment authorized for use has “diminished potency” against the omicron variant.

Regeneron CEO Len Schleifer sits down with CNBC's Meg Tirrell and the 'Squawk Box' team to break down the company's latest data on its Covid-19 antibody's defense against the omicron variant.

CEO Leonard Schleifer told CNBC Regeneron plans to conduct trials on the new antibodies in the first quarter of 2022.

CNBC's Meg Tirrell joins 'Squawk Box' to report on the latest news from Regeneron, which found that its Covid-19 antibody has diminished potency against the worrisome omicron variant.

We believe that there are other stocks that are currently better valued than Starbucks' stock. SBUX's current price-to-operating income ratio (P/EBIT) of 33.5x is higher than levels of 22.4x for Pione

Progressives and government watchdog groups on Wednesday condemned House Speaker Nancy Pelosi''s defense of individual stock trading by members of Congress, days after an extensive report revealed dozens of conflicts of interest by lawmakers who own stocks related to the healthcare industry and other sectors Congress is supposed to regulate. After being asked by Business Insider at her weekly press conference whether members of Congress and their spouses should be barred from trading stocks, Pelosi said the practice should be permitted to continue because "we are a free market economy." REPORTER: "Should members of congress and their spouses be banned from trading individual stocks while serving in congress?"\n\nPELOSI: "NoWe are a free market economy. They should be able to participate in that."pic.twitter.com/2SNqSCwFEU Townhall.com (@Townhall.com) 1639585364 Speaking to Business Insider after the press conference, Pelosi''s spokesperson said the STOCK Act which was passed in 2012 and requires members to disclose security transactions and ensure they don''t make individual stock trades based on knowledge they gain as lawmakersprevents members of Congress from insider trading.

Livforsakringsbolaget Skandia Omsesidigt grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 35.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,916 shares of the biopharmaceutical companys stock after acquiring an additional 2,610 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigts holdings in Regeneron []

Marshall Financial Group LLC raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.5% in the third quarter, Holdings Channel.com reports. The firm owned 1,454 shares of the biopharmaceutical companys stock after buying an additional 114 shares during the period. Marshall Financial Group LLCs holdings in Regeneron Pharmaceuticals were worth $880,000 as of []

Westpac Banking Corp lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 29.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 23,060 shares of the biopharmaceutical companys stock after selling 9,447 shares during the period. Westpac Banking Corps holdings in Regeneron Pharmaceuticals were []

Nasdaq Pares Losses After Early Dive; Nucor, Regeneron Strong; Cadence Makes Key Test Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists, inves

New Jersey, United States,- Verified Market Research has recently published a research report titled, Diabetic Retinopathy Market Size, and Forecast 2021-2028, Breakdown Data by Manufacturers, Key Regions, Types and Application. Primary and secondary research methodologies have been used to formulate

Related Stocks: DT , UBER , DOMO , CNC , MELI , REGN , FIVN , KGDEF , CCO , BEKE , WXIBF , PTON ,

Regeneron (REGN) closed at $660.15 in the latest trading session, marking a -1.4% move from the prior day.

Wall Street analysts predict that Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will post earnings per share of $18.80 for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for Regeneron Pharmaceuticals’ earnings. The highest EPS estimate is $21.71 and the lowest is $16.03. Regeneron Pharmaceuticals posted earnings of $9.53 per share during the same […]

Schaper Benz & Wise Investment Counsel Inc. WI grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.0% in the third quarter, according to its most recent filing with the SEC. The fund owned 20,863 shares of the biopharmaceutical company’s stock after acquiring an additional 198 shares during the period. Schaper Benz & […]